Company intelligence / Profile preview

AlleyCorp

New York, New York, United Statesalleycorp.com ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

AlleyCorp incubated Transcend Therapeutics in 2021. In early clinical trials, Transcend’s lead compound TSND‑201 (methylone) showed rapid efficacy in PTSD patients with statistically significant improvement over placebo by Day 10. The company plans to initiate a final Phase 3 program with the FDA. Other health/biotech investments are at various stages from preclinical to commercial.

Therapeutic areas: OtherPsychiatryNeurology
Modalities: Small moleculePsychoactive drug
Industry: Investors

Partnerships

Orange Grove Bio and Alexandria Venture Investments for academic translation partnerships with Albert Einstein College of Medicine

Beyond the preview

Go deeper on AlleyCorp.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlleyCorp.

Explore the full profile